With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Educational research only - not investment advice, an offer, or a trade instruction. Confirm current data and do your own due diligence before acting.
BIIB trades against a final fair-value range of $192.23-$314.03, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.
Leqembi adoption is stunted by administration bottlenecks or safety concerns while the MS franchise erodes faster than modeled, forcing sustained margin compression and multiple degradation.
Severe administration bottlenecks and ARIA safety concerns permanently stunt Leqembi uptake.
Legacy MS products lose market share far faster than expected, crashing trailing cash flows before pipeline kicks in.
Global structural drug pricing pressures disproportionately target Biogen's high-margin neurology portfolio.
| Line item | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
|---|---|---|---|---|---|
| Revenue | $10.17B | $9.84B-3.2% | $9.68B-1.6% | $9.89B+2.2% | -0.9% |
| Gross profit | $7.90B | $7.30B | $7.37B | $7.49B | -1.8% |
| Operating income | $2.90B | $1.85B | $2.28B | $2.47B | -5.2% |
| Net income | $3.05B | $1.16B-62.0% | $1.63B+40.5% | $1.29B-20.9% | -24.9% |
| EPS (diluted) | $20.87 | $7.97 | $11.18 | $8.79 | -25.0% |
| EBITDA | $4.36B | $2.04B | $2.83B | $2.60B | -15.8% |
| R&D | $2.23B | $2.45B | $1.98B | $1.78B | -7.3% |
| SG&A | $2.40B | $2.55B | $2.40B | $2.43B | +0.4% |
Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
| Deterioration versus the report thesis |
| Market share in Alzheimer's is lost to emerging competitor products. | Monitor | Deterioration versus the report thesis |
| Faster-than-expected erosion of legacy products like Tecfidera and Tysabri. | Monitor | Deterioration versus the report thesis |
